Sort   by:  
 Page size 
UnknownNeoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
Not available
S-EPMC11405264 | biostudies-literature
UnknownActivity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.
Not available
S-EPMC5048757 | biostudies-literature
UnknownDifferential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
Not available
S-EPMC5528644 | biostudies-literature
UnknownAssociation Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Not available
S-EPMC5885201 | biostudies-literature
UnknownAnalysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma.
Not available
S-EPMC6966626 | biostudies-literature
UnknownHigher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Not available
S-EPMC9189855 | biostudies-literature
UnknownPDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.
Not available
S-EPMC8220213 | biostudies-literature
UnknownPre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
Not available
S-EPMC6551453 | biostudies-literature
UnknownTranscriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition.
Not available
S-EPMC7171183 | biostudies-literature
UnknownThe molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Not available
S-EPMC10024679 | biostudies-literature
Sort   by:  
 Page size